No headlines found.
Business Wire (Fri, 13-Mar 8:00 AM ET)
KORU Medical Systems Announces CEO Transition
Business Wire (Thu, 12-Mar 4:08 PM ET)
Business Wire (Thu, 12-Mar 4:05 PM ET)
KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Business Wire (Thu, 26-Feb 4:05 PM ET)
Business Wire (Thu, 29-Jan 4:05 PM ET)
Business Wire (Mon, 12-Jan 8:00 AM ET)
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 5-Jan 7:00 AM ET)
Business Wire (Tue, 30-Dec 4:05 PM ET)
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Koru Medical Systems trades on the NASDAQ stock market under the symbol KRMD.
As of March 24, 2026, KRMD stock price climbed to $4.45 with 68,777 million shares trading.
KRMD has a beta of 1.30, meaning it tends to be more sensitive to market movements. KRMD has a correlation of 0.18 to the broad based SPY ETF.
KRMD has a market cap of $206.35 million. This is considered a Small Cap stock.
Last quarter Koru Medical Systems reported $11 million in Revenue and $.01 earnings per share. This fell short of revenue expectation by $-850 and exceeded earnings estimates by $.03.
In the last 3 years, KRMD traded as high as $6.61 and as low as $1.86.
The top ETF exchange traded funds that KRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
KRMD has outperformed the market in the last year with a return of +58.4%, while the SPY ETF gained +17.3%. However, in the most recent history, KRMD shares have underperformed the stock market with its stock returning -31.7% in the last 3 month period and -3.5% for the last 2 week period, while SPY has returned -4.6% and -3.3%, respectively.
KRMD support price is $4.26 and resistance is $4.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KRMD shares will trade within this expected range on the day.